| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Former CFO & Treasurer | CFO & Treasurer | CFO, Secretary & Treasurer
1 company
R. LaDuane Clifton is Former CFO & Treasurer at ZVRA. R. LaDuane Clifton's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.5M at current prices.
Our model assigns R. LaDuane Clifton a middling insider score of 55/100, based on 14 past trades. Over a 12-month horizon, 35.7% of those trades were profitable, with an average 12-month return of -7.6%.
Net of sales, the ZVRA filings show accumulation of 51,415 shares.
R. LaDuane Clifton has 45 Form 4 filings on record from April 2015 to December 2025, all as Former CFO & Treasurer at Zevra Therapeutics (ZVRA), 2015–2025.
The 56 reported transactions were 37 open-market purchases, 15 option or other derivative awards, 2 option exercises and 1 tax withholding, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 29 purchases worth about $105K and 1 sale worth about $86K.
The largest open-market purchase was 2,740 shares of ZVRA at an average $4.95 on May 18, 2023, about $14K. Twelve months later ZVRA was down 6%.
The only open-market sale was 11,000 shares of ZVRA at an average $7.86 on February 13, 2025, about $86K. Twelve months later ZVRA was up 6%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | ZVRA Zevra Therapeutics, Inc. | CFO & Treasurer | Sell10b5-1 | 11,000 | $7.86 | $86,471.00 | -17.6% | +1.9% | +6.4% | |
| Jul 17, 2024 | ZVRA Zevra Therapeutics, Inc. | CFO & Treasurer | Buy | 2,000 | $6.77 | $13,540.00 | +12.1% | +27.2% | +92.1% | |
| Sep 6, 2023 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 1,000 | $4.96 | $4,959.10 | +7.0% | +1.6% | +45.2% | |
| May 18, 2023 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 2,740 | $4.95 | $13,561.95 | +24.9% | +2.8% | -6.3% | |
| Mar 10, 2023 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 1,725 | $4.15 | $7,158.75 | +18.6% | +33.9% | +47.7% | |
| Jan 13, 2023 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 635 | $5.81 | $3,689.83 | +7.3% | +13.9% | +7.2% | |
| Sep 30, 2022 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 1,000 | $5.98 | $5,981.20 | +14.1% | -26.9% | -22.8% | |
| May 18, 2022 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 1,200 | $5.00 | $5,999.04 | +22.9% | +16.0% | +6.1% | |
| Nov 18, 2021 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 510 | $8.29 | $4,227.90 | +10.8% | -27.6% | -44.0% | |
| Sep 29, 2021 | ZVRA Zevra Therapeutics, Inc. | CFO, Secretary & Treasurer | Buy | 215 | $9.38 | $2,016.70 | +4.8% | -6.2% | -35.2% |